A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors

Sponsor:

BioNTech Pharmaceuticals

Sponsor Study ID:

BNT317-01/PM1086-A001

CTO #:

104114

NCT Number:

NCT99999999

Phase:

I

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder; Breast; Cervix Uteri; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Ovary; Pancreas; Prostate; Rectum; Small Intestine

Study Objectives:

To determine the safety profile, and tolerability of BNT317 in patients with advanced solid tumors. To determine the MTD or the RP2D of BNT317 in patients with advanced solid tumors.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)